TheraRadar
Data updated: May 26, 2026

KORSUVA (difelikefalin acetate)

First-in-Class Breakthrough Therapy Priority Review
Renal Approved 2021-08-23

Korsuva helps patients with moderate-to-severe itching related to chronic kidney disease who are currently undergoing hemodialysis. It is used to manage this persistent pruritus in adult patients. However, it is not recommended for those receiving peritoneal dialysis, as it has not been studied in that population.

Source: FDA Label • VIFOR INTL

How KORSUVA Works

This medication works by targeting and activating kappa opioid receptors in the body. While it acts as an agonist for these specific receptors, the exact process by which this activity reduces itching in patients is not currently known.

1
Indication
--
Phase 3 Trials
1
Priority Reviews
4
Years on Market

Details

Status
Prescription
First Approved
2021-08-23
Patent Cliff
2027

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
INTRAVENOUS
Dosage Forms
SOLUTION

Companies

Active Ingredient: DIFELIKEFALIN ACETATE

KORSUVA Approval History

2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
2 FDA actions from 2021 to 2025
Mar 2025 SUPPL
Mfg · Manufacturing (CMC)
Aug 2021 ORIGINAL Priority
New Drug · Type 1 - New Molecular Entity

What KORSUVA Treats

2 indications

KORSUVA is approved for 2 conditions since its original approval in 2021. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Pruritus
  • Chronic Kidney Disease
Source: FDA Label

KORSUVA Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to KORSUVA

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AURYXIA
FERRIC CITRATE
1 shared
KERYX BIOPHARMS
Shared indications:
BYLVAY
ODEVIXIBAT
1 shared
IPSEN
Shared indications:
Pruritus
CROTAN
CROTAMITON
1 shared
LEGACY PHARMA
Shared indications:
Pruritus
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

KORSUVA FDA Label Details

Indications & Usage

FDA Label (PDF)

KORSUVA is indicated for the treatment of Pruritus; Chronic Kidney Disease.

View full patent landscape →
12 OB patents · 4 families · 98 international docs across 27 countries

KORSUVA Patents & Exclusivity

Latest Patent: Nov 2027
Exclusivity: Aug 2026

Patents (12 active)

US10793596 Expires Nov 12, 2027
US10138270 Expires Nov 12, 2027
US10017536 Expires Nov 12, 2027
US9359399 Expires Nov 12, 2027
US9334305 Expires Nov 12, 2027
US8536131 Expires Nov 12, 2027
US8486894 Expires Nov 12, 2027
US8236766 Expires Nov 12, 2027
US8217007 Expires Nov 12, 2027
US7727963 Expires Nov 12, 2027
US7713937 Expires Nov 12, 2027
US7402564 Expires Nov 12, 2027

Exclusivity

NCE Until Aug 2026
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for KORSUVA

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2027
  • 12 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • 20 similar drugs
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.